Sapacitabine

DRUG6 trials

Sponsors

Cyclacel Pharmaceuticals, Inc., M.D. Anderson Cancer Center, Dana-Farber Cancer Institute

Conditions

Acute Myeloid LeukemiaBreast CancerCutaneous T-cell Lymphoma (CTCL)LeukemiaLeukemiasMyelodysplastic SyndromesNon-small Cell Lung Cancer

Phase 1

Safety and Pharmacology Study of Sapacitabine to Treat Advanced Leukemias or Myelodysplastic Syndromes

CompletedNCT00380653

Cyclacel Pharmaceuticals, Inc.Leukemias, Myelodysplastic Syndromes

Start: 2006-01-31End: 2009-06-30Updated: 2021-12-13

Olaparib + Sapacitabine in BRCA Mutant Breast Cancer

Active, not recruitingNCT03641755

Dana-Farber Cancer InstituteBreast Cancer

Start: 2018-10-01End: 2026-10-22Updated: 2026-02-23

Phase 2

A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma

TerminatedNCT00476554

Cyclacel Pharmaceuticals, Inc.Cutaneous T-cell Lymphoma (CTCL)

Start: 2007-04-30End: 2012-03-01Updated: 2021-12-22

A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer

TerminatedNCT00885963

Cyclacel Pharmaceuticals, Inc.Non-small Cell Lung Cancer

Start: 2008-12-01End: 2013-12-23Updated: 2021-12-22

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

TerminatedNCT01253460

M.D. Anderson Cancer CenterLeukemia

Start: 2011-08-22End: 2019-02-13Updated: 2019-09-06

Phase 3

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

CompletedNCT01303796

Cyclacel Pharmaceuticals, Inc.Acute Myeloid Leukemia

Start: 2011-10-01End: 2017-07-31Updated: 2022-06-22

Related Papers

Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS)

Cancer2021-08-237 citations

Abstract 4633: The DNA strand breaking nucleoside analogue sapacitabine sensitizes Brca2-deficient ovarian cancer cells and synergizes with PARP inhibitors

Cancer Research2016-07-15

Abstract 2551: Brca1-deficient ovarian cancer cells are sensitized to the DNA-strand-breaking nucleoside analog sapacitabine that synergizes with PARP inhibition

Cancer Research2015-08-01